Mechanisms Operative in the Antitumor Activity of Temozolomide in Glioblastoma Multiforme

Purpose:Glioblastoma multiforme (GBM) is the most frequent and incurable brain tumor in adults. Although temozolomide (TMZ) does not cure GBM, it has demonstrated anti-GBM activity and has improved survival (8–14 months) and quality of life. We studied the mechanisms by which TMZ affects 2 human GBM cell lines; U251-MG and U87-MG, aiming to unravel the drug-activated cascades to enable the development of combination therapies that will improve the efficacy of TMZ. Materials and Methods:The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium assay was used to assess cell viability. Modulation of gene expression by TMZ therapy was assayed by gene profiling and verified by quantitative real-time polymerase chain reaction. Protein levels influenced by the treatment were studied by Western blots and immunocytochemistry. Results:Increasing concentrations of TMZ decreased cell viability in a concentration-dependent manner. The expression of 1,886 genes was altered >2-fold after TMZ treatment. We focused on the 81 genes similarly altered by TMZ treatment in both cell lines to neutralize tissue-specific characteristics. Fourteen target genes of hypoxia-inducible factor (HIF-1), were found to be up-regulated after TMZ treatment including vascular endothelial growth factor (VEGF). HIF-1&agr; expression was constant at the mRNA level; however, its post-treatment protein levels increased compared with those of untreated control cells. Discussion:The genetic analyses suggest that treatment with TMZ activates stress mechanisms in GBM cells that include the angiogenesis-inducing proteins HIF-1&agr; and VEGF. We propose that treatment with TMZ be supplemented with either an antibody to VEGF or down-regulators of HIF-1&agr; to improve clinical results of TMZ in the treatment of GBM.

[1]  S. Fulda,et al.  Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance , 2007, Oncogene.

[2]  J. Jean,et al.  Hypoxia results in an HIF-1-dependent induction of brain-specific aldolase C in lung epithelial cells. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[3]  R. Weimann,et al.  Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer , 2006, British Journal of Cancer.

[4]  Isabelle Camby,et al.  Present and potential future issues in glioblastoma treatment , 2006, Expert review of anticancer therapy.

[5]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[6]  M. Weller,et al.  O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells , 2006, Journal of neurochemistry.

[7]  G. F. Wagner,et al.  Hypoxia-inducible factor-1-mediated activation of stanniocalcin-1 in human cancer cells. , 2005, Endocrinology.

[8]  A. Mobasheri,et al.  Hypoxia inducible factor-1 and facilitative glucose transporters GLUT1 and GLUT3: putative molecular components of the oxygen and glucose sensing apparatus in articular chondrocytes. , 2005, Histology and histopathology.

[9]  N. Amariglio,et al.  The nuclear-envelope protein and transcriptional repressor LAP2β interacts with HDAC3 at the nuclear periphery, and induces histone H4 deacetylation , 2005, Journal of Cell Science.

[10]  Manish Gala,et al.  Induction of interleukin-8 preserves the angiogenic response in HIF-1α–deficient colon cancer cells , 2005, Nature Medicine.

[11]  J. Hecht,et al.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[13]  J. Itskovitz‐Eldor,et al.  CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. , 2005, Stem cells.

[14]  N. Amariglio,et al.  Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. , 2005, Cancer research.

[15]  N. Banik,et al.  Dexamethasone protected human glioblastoma U87MG cells from temozolomide induced apoptosis by maintaining Bax:Bcl-2 ratio and preventing proteolytic activities , 2004, Molecular Cancer.

[16]  G. Koomen,et al.  Synthesis and Antitumor Activity of Methyltriazene Prodrugs Simultaneously Releasing DNA-Methylating Agents and the Antiresistance Drug O6-Benzylguanine , 2004 .

[17]  David M Jablons,et al.  Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Luca Regli,et al.  Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.

[19]  I. Germano,et al.  Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. , 2003, Journal of neurosurgery.

[20]  D. Meruelo,et al.  Enhanced ubiquitinylation of heat shock protein 90 as a potential mechanism for mitotic cell death in cancer cells induced with hypericin. , 2003, Cancer research.

[21]  L. Gunaratnam,et al.  Hypoxia Inducible Factor Activates the Transforming Growth Factor-α/Epidermal Growth Factor Receptor Growth Stimulatory Pathway in VHL-/- Renal Cell Carcinoma Cells* , 2003, Journal of Biological Chemistry.

[22]  Z. Dong,et al.  Apoptosis-resistance of hypoxic cells: multiple factors involved and a role for IAP-2. , 2003, The American journal of pathology.

[23]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[24]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[25]  W. Kaelin,et al.  HIF hydroxylation and the mammalian oxygen-sensing pathway. , 2003, The Journal of clinical investigation.

[26]  E Pawlak,et al.  Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids , 2003, British Journal of Cancer.

[27]  D. Mottet,et al.  CoCl2, a Chemical Inducer of Hypoxia‐Inducible Factor‐1, and Hypoxia Reduce Apoptotic Cell Death in Hepatoma Cell Line HepG2 , 2002, Annals of the New York Academy of Sciences.

[28]  S. Finkelstein,et al.  Multifaceted resistance of gliomas to temozolomide. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  Franklin Peale,et al.  In silico data filtering to identify new angiogenesis targets from a large in vitro gene profiling data set. , 2002, Physiological genomics.

[30]  S. Gerson Clinical relevance of MGMT in the treatment of cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Dena Leshkowitz,et al.  Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene, RTP801, Involved in Apoptosis , 2002, Molecular and Cellular Biology.

[32]  Reto Meuli,et al.  Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Harris,et al.  Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. , 2001, Cancer research.

[34]  K. Srivenugopal,et al.  Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  W. Sly,et al.  Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. , 2001, The American journal of pathology.

[36]  A. Harris,et al.  Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling , 2000, Oncogene.

[37]  Scar,et al.  Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.

[38]  K. Hillan,et al.  Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. , 1999, Anticancer research.

[39]  G. Weiss,et al.  Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  F. Ismail-Beigi,et al.  Regulation of glucose transport by hypoxia. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  A. MacKenzie,et al.  The inhibitors of apoptosis (IAPs) and their emerging role in cancer , 1998, Oncogene.

[42]  R. McLendon,et al.  DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[44]  B. Teicher,et al.  Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma , 1996, Cancer Chemotherapy and Pharmacology.

[45]  G. Semenza,et al.  Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. , 1994, The Journal of biological chemistry.

[46]  E. Newlands,et al.  Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. , 1993, British Journal of Cancer.

[47]  Bing Li,et al.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.

[48]  A. Pegg,et al.  Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. , 1990, Cancer research.

[49]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.